| Title | Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. |
| Publication Type | Journal Article |
| Year of Publication | 2021 |
| Authors | Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham C-AD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Seifert H, Thabit AK, Villegas MVirginia, Westblade LF, Nicolau DP |
| Corporate Authors | ERACE-PA Global Study Group |
| Journal | Antimicrob Agents Chemother |
| Volume | 65 |
| Issue | 11 |
| Pagination | e0120421 |
| Date Published | 2021 Oct 18 |
| ISSN | 1098-6596 |
| Abstract | The present study evaluated the potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints. |
| DOI | 10.1128/AAC.01204-21 |
| Alternate Journal | Antimicrob Agents Chemother |
| PubMed ID | 34398670 |
Related Faculty:
Lars Westblade, Ph.D.